1. Home
  2. ALAR vs NSRX Comparison

ALAR vs NSRX Comparison

Compare ALAR & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alarum Technologies Ltd.

ALAR

Alarum Technologies Ltd.

N/A

Current Price

$7.39

Market Cap

58.8M

Sector

Technology

ML Signal

N/A

NSRX

Nasus Pharma Ltd. Ordinary Shares

N/A

Current Price

$4.86

Market Cap

53.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALAR
NSRX
Founded
2013
2019
Country
Israel
Israel
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.8M
53.5M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ALAR
NSRX
Price
$7.39
$4.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$27.00
$20.50
AVG Volume (30 Days)
30.1K
3.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$31.17
N/A
Revenue Next Year
$30.14
N/A
P/E Ratio
$44.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.45
$3.99
52 Week High
$18.00
$9.99

Technical Indicators

Market Signals
Indicator
ALAR
NSRX
Relative Strength Index (RSI) 51.31 41.33
Support Level $7.27 N/A
Resistance Level $7.75 $6.39
Average True Range (ATR) 0.44 0.70
MACD 0.15 0.01
Stochastic Oscillator 64.74 35.08

Price Performance

Historical Comparison
ALAR
NSRX

About ALAR Alarum Technologies Ltd.

Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: